{"title":"依多沙班的第三阶段研究","authors":"Iñaki Lekuona Goya","doi":"10.1016/S1131-3587(16)30019-X","DOIUrl":null,"url":null,"abstract":"<div><p>Edoxaban has been studied extensively in phase-III trials, for example, for nonvalvular atrial fibrillation (the ENGAGE AF-TIMI 48 study), for the prevention of recurrent venous thromboembolism (the Hokusai-VTE study) and for the prevention of thromboembolism after orthopedic surgery (the STARS study). In addition, a number of recently published, subanalyses of pivotal trials deserve consideration: these concern different subtypes of stroke and peripheral embolism in patients receiving amiodarone and the treatment of elderly patients.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(16)30019-X","citationCount":"0","resultStr":"{\"title\":\"Estudios en fase III del edoxabán\",\"authors\":\"Iñaki Lekuona Goya\",\"doi\":\"10.1016/S1131-3587(16)30019-X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Edoxaban has been studied extensively in phase-III trials, for example, for nonvalvular atrial fibrillation (the ENGAGE AF-TIMI 48 study), for the prevention of recurrent venous thromboembolism (the Hokusai-VTE study) and for the prevention of thromboembolism after orthopedic surgery (the STARS study). In addition, a number of recently published, subanalyses of pivotal trials deserve consideration: these concern different subtypes of stroke and peripheral embolism in patients receiving amiodarone and the treatment of elderly patients.</p></div>\",\"PeriodicalId\":34926,\"journal\":{\"name\":\"Revista Espanola de Cardiologia Suplementos\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1131-3587(16)30019-X\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola de Cardiologia Suplementos\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S113135871630019X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Cardiologia Suplementos","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S113135871630019X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Edoxaban has been studied extensively in phase-III trials, for example, for nonvalvular atrial fibrillation (the ENGAGE AF-TIMI 48 study), for the prevention of recurrent venous thromboembolism (the Hokusai-VTE study) and for the prevention of thromboembolism after orthopedic surgery (the STARS study). In addition, a number of recently published, subanalyses of pivotal trials deserve consideration: these concern different subtypes of stroke and peripheral embolism in patients receiving amiodarone and the treatment of elderly patients.
期刊介绍：
Revista Española de Cardiología, is an international scientific journal dealing with cardiovascular medicine. Revista Española de Cardiología, the official publication of the Spanish Society of Cardiology, publishes research articles related to cardiovascular diseases. Articles are published in Spanish for the paper edition and in both Spanish and English in the electronic edition, which is available on the Internet. Regular sections include original articles reporting clinical or basic research, brief reports, review articles, editorials and letters to the Editor.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
